Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Gynecologic 2Genitourinary 2Dermatologic 2Breast 2Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Endometrial Neoplasms 1

Interventions

Paclitaxel 268Carboplatin 264Cisplatin 194Bevacizumab 135pembrolizumab 99Surveys and Questionnaires 84Radiotherapy 77Cyclophosphamide 75olaparib 67Blood Specimen Collection 65Drug Therapy 62Hyperthermic Intraperitoneal Chemotherapy 60Gemcitabine 60niraparib 56Topotecan 56Brachytherapy 54liposomal doxorubicin 52Taxes 47Docetaxel 46Magnetic Resonance Spectroscopy 43Letrozole 36Cytoreduction Surgical Procedures 36Filgrastim 33Biopsy 33Surgical Procedures, Operative 32durvalumab 31Specimen Handling 31Doxorubicin 31Nivolumab 30Albumin-Bound Paclitaxel 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × sitravatinib × Gynecologic × Clear all
NCT05614453 2023-06-29

ITTACC

Australia New Zealand Gynaecological Oncology Group

Phase 2 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT05419817 2023-02-27

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

University of Pittsburgh

Phase 2 Withdrawn
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡